|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Hannenhalli S and Kaestner KH: The
evolution of Fox genes and their role in development and disease.
Nat Rev Genet. 10:233–240. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Costa RH, Grayson DR and Darnell JE Jr:
Multiple hepatocyte-enriched nuclear factors function in the
regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell
Biol. 9:1415–1425. 1989.PubMed/NCBI
|
|
4
|
Carroll JS, Liu XS, Brodsky AS, et al:
Chromosome-wide mapping of estrogen receptor binding reveals
long-range regulation requiring the forkhead protein FoxA1. Cell.
122:33–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Q, Li W, Zhang Y, et al: Androgen
receptor regulates a distinct transcription program in
androgen-independent prostate cancer. Cell. 138:245–256. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans RM: The steroid and thyroid hormone
receptor superfamily. Science. 240:889–895. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vilquin P, Villedieu M, Grisard E, et al:
Molecular characterization of anastrozole resistance in breast
cancer: pivotal role of the Akt/mTOR pathway in the emergence of de
novo or acquired resistance and importance of combining the
allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J
Cancer. 133:1589–1602. 2013. View Article : Google Scholar
|
|
8
|
Holmes KA, Hurtado A, Brown GD, et al:
Transducin-like enhancer protein 1 mediates estrogen receptor
binding and transcriptional activity in breast cancer cells. Proc
Natl Acad Sci USA. 109:2748–2753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaughan L, Stockley J, Coffey K, et al:
KDM4B is a master regulator of the estrogen receptor signalling
cascade. Nucleic Acids Res. 41:6892–6904. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rahimi M, George J and Tang C: EGFR
variant-mediated invasion by enhanced CXCR4 expression through
transcriptional and post-translational mechanisms. Int J Cancer.
126:1850–1860. 2010.PubMed/NCBI
|
|
11
|
Theodorou V, Stark R, Menon S and Carrol
JS: GATA3 acts upstream of FOXA1 in mediating ESR1 binding by
shaping enhancer accessibility. Genome Res. 23:12–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Srijaipracharoen S, Tangjitgamol S,
Tanvanich S, et al: Expression of ER, PR, and Her-2/neu in
endometrial cancer: a clinicopathological study. Asian Pac J Cancer
Prev. 11:215–220. 2010.PubMed/NCBI
|
|
13
|
Wolf I, Bose S, Williamson EA, et al:
FOXA1: Growth inhibitor and a favorable prognostic factor in human
breast cancer. Int J Cancer. 120:1013–1022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Creasman W: Revised FIGO staging for
carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Badve S, Turbin D, Thorat MA, et al: FOXA1
expression in breast cancer - correlation with luminal subtype A
and survival. Clin Cancer Res. 13:4415–4421. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishida M: The Ishikawa cells from birth
to the present. Hum Cell. 15:104–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Way DL, Grosso DS, Davis JR, et al:
Characterization of a new human endometrial carcinoma (RL95-2)
established in tissue culture. In Vitro. 19:147–158. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuramoto H: Studies of the growth and
cytogenetic properties of human endometrial adenocarcinoma in
culture and its development into an established line. Acta Obstet
Gynaecol Jpn. 19:47–58. 1972.PubMed/NCBI
|
|
19
|
Kawase M, Toyama T, Takahashi S, et al:
FOXA1 expression after neoadjuvant chemotherapy is a prognostic
marker in estrogen receptor-positive breast cancer. Breast Cancer.
Jun 16–2013.(Epub ahead of print).
|
|
20
|
Hurtado A, Holmes KA, Ross-Innes CS, et
al: FOXA1 is a key determinant of estrogen receptor function and
endocrine response. Nat Genet. 43:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McConechy MK, Ding J, Cheang MC, et al:
Use of mutation profiles to refine the classification of
endometrial carcinomas. J Pathol. 228:20–30. 2012.PubMed/NCBI
|
|
23
|
Alvarez T, Miller E, Duska L and Oliva E:
Molecular profile of grade 3 endometrioid endometrial carcinoma: is
it a type I or type II endometrial carcinoma? Am J Surg Pathol.
36:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clarke BA and Gilks CB: Endometrial
carcinoma: controversies in histopathological assessment of grade
and tumour cell type. J Clin Pathol. 63:410–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bernardo GM and Keri RA: FOXA1: a
transcription factor with parallel functions in development and
cancer. Biosci Rep. 32:113–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abe Y, Ijichi N, Ikeda K, et al: Forkhead
box transcription factor, forkhead box A1, shows negative
association with lymph node status in endometrial cancer, and
represses cell proliferation and migration of endometrial cancer
cells. Cancer Sci. 103:806–812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uharcek P: Prognostic factors in
endometrial carcinoma. J Obstet Gynaecol Res. 34:776–783. 2008.
View Article : Google Scholar
|
|
28
|
Neben K, Schnittger S, Brors B, et al:
Distinct gene expression patterns associated with FLT3- and
NRAS-activating mutations in acute myeloid leukemia with normal
karyotype. Oncogene. 24:1580–1588. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin L, Miller CT, Contreras JI, et al: The
hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on
chromosome band 14q13 is amplified and overexpressed in esophageal
and lung adenocarcinomas. Cancer Res. 62:5273–5279. 2002.PubMed/NCBI
|
|
30
|
Coulouarn C, Factor VM, Andersen JB, et
al: Loss of miR-122 expression in liver cancer correlates with
suppression of the hepatic phenotype and gain of metastatic
properties. Oncogene. 28:3526–3536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
DeGraff DJ, Clark PE, Cates JM, et al:
Loss of the urothelial differentiation marker FOXA1 is associated
with high grade, late stage bladder cancer and increased tumor
proliferation. PLoS One. 7:e366692012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song Y, Washington MK and Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal
transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Early Breast Cancer Trialists’
Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
34
|
Williamson EA, Wolf I, O’Kelly J, et al:
BRCA1 and FOXA1 proteins coregulate the expression of the cell
cycle-dependent kinase inhibitor p27(Kip1). Oncogene. 25:1391–1399.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Q, Zhang Y, Fu J, et al: FOXA1 mediates
p16(INK4a) activation during cellular senescence. EMBO J.
32:858–873. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Prat J, Gallardo A, Cuatrecasas M and
Catasus L: Endometrial carcinoma: pathology and genetics.
Pathology. 39:72–87. 2007. View Article : Google Scholar
|
|
37
|
Gururaj AE, Rayala SK, Vadlamudi RK and
Kumar R: Novel mechanisms of resistance to endocrine therapy:
genomic and nongenomic considerations. Clin Cancer Res.
12:S1001–S1007. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cirillo LA, Lin FR, Cuesta I, et al:
Opening of compacted chromatin by early developmental transcription
factors HNF3 (FoxA) and GATA-4. Mol Cell. 9:279–289. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lupien M, Eeckhoute J, Meyer CA, et al:
FoxA1 translates epigenetic signatures into enhancer-driven
lineage-specific transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kong SL, Li G, Loh SL, et al: Cellular
reprogramming by the conjoint action of ERalpha, FOXA1, and GATA3
to a ligand-inducible growth state. Mol Syst Biol. 7:5262011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Green KA and Carroll JS:
Oestrogen-receptor-mediated transcription and the influence of
co-factors and chromatin state. Nat Rev Cancer. 7:713–722. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ross-Innes CS, Stark R, Teschendorff AE,
et al: Differential oestrogen receptor binding is associated with
clinical outcome in breast cancer. Nature. 481:389–393.
2012.PubMed/NCBI
|
